Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Savara Inc
SVRA | US
5.12
USD0.18
3.64%
SVRA | US
About Savara Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
24/04/2026
Close
5.12
Open
5.00
High
5.19
Low
4.94
Savara Inc. a clinical stage biopharmaceutical company focuses on rare respiratory diseases. The company's lead product candidate is molgramostim an inhaled granulocyte-macrophage colony-stimulating factor which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Austin Texas.
View LessSVRA | US
Risk
57.2
Sharpe
0.77
Luna's Score
46/100
Recommendation
Hold
Luna says (SVRA | US)
What's Working
Low Debt to Asset (< 0.2)
What's not Working
Price Below SMA10D
High Short-term Volatility
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
58.6%1 month
57.2%3 months
53.7%6 months
60.8%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
5.91
Debt to equity
0.26
Debt to assets
0.19
Ent. to EBITDA
-4.76
Ent. to rev.
11.91
PEG
-
Other Fundamentals
EBITDA
-80.42M
MarketCap
842.76M
MarketCap(USD)
842.76M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-79.48
Short ratio
10.15
Short perc.
8.54
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
1.33
Range1M
1.39
Range3M
1.61
Volumes: Market Activity
Rel. volume
0.71
Price X volume
4.67M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -4.76 | - | Cheaper |
| Ent. to Revenue | 11.91 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 5.91 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 53.73 | - | Lower Risk |
| Debt to Equity | 0.26 | -1.23 | Expensive |
| Debt to Assets | 0.19 | 0.25 | Cheaper |
| Market Cap | 842.76M | - | Emerging |
